Akebia Therapeutics logo
Akebia Therapeutics AKBA
$ 0.39 -7.14%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Akebia Therapeutics Book Value | AKBA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.
What is included in book value
  • Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
  • Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
Features of the metric
  • Assessment of the company's "real" value
    Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
  • Comparison with market capitalization
    Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
  • Indicator of financial stability
    If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
  • Key component for financial ratios
    Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Akebia Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
32.6 M -49.2 M -30.6 M 5.23 M 74 M 248 M 395 M 636 M 119 M 68.1 M 131 M 104 M 30.8 M -2.68 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
636 M -49.2 M 126 M

Quarterly Book Value Akebia Therapeutics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
20.4 M 25 M 27.4 M 32.6 M 41.6 M 29.2 M 24.6 M -49.2 M -50.4 M -33.8 M -27.3 M -30.6 M -39.4 M -26.8 M -19.1 M 5.23 M 8.26 M 58.9 M 22.6 M 74 M 137 M 175 M 214 M 248 M 318 M 370 M 396 M 395 M 468 M 519 M 566 M 636 M 143 M 166 M 197 M 123 M 99.9 M 57 M 30.6 M 68.1 M 101 M 133 M 168 M 131 M 145 M 150 M 94.6 M 104 M 114 M 122 M 128 M 30.8 M 30.8 M 30.8 M 30.8 M - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
636 M -50.4 M 126 M

Book Value of other stocks in the Biotechnology industry

Issuer Book Value Price % 24h Market Cap Country
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
302 M $ 24.73 -1.9 % $ 783 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
12 M $ 0.32 1.02 % $ 2.52 M israelIsrael
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
148 M $ 2.05 -15.81 % $ 27.3 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
61 M $ 76.99 0.03 % $ 997 M usaUSA
Curis Curis
CRIS
5.46 M $ 0.44 -6.31 % $ 5.79 M usaUSA
CorMedix CorMedix
CRMD
405 M $ 5.25 4.23 % $ 378 K usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
78.1 M $ 3.07 -4.66 % $ 255 M usaUSA
Champions Oncology Champions Oncology
CSBR
4.07 M $ 4.34 -1.36 % $ 60 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
597 M $ 10.9 -2.5 % $ 13.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
315 M $ 96.15 0.67 % $ 4.83 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
-51 M $ 3.85 -2.66 % $ 1.18 B usaUSA
Dyadic International Dyadic International
DYAI
1.23 M $ 0.29 -6.53 % $ 10.5 M usaUSA
Merck & Co. Merck & Co.
MRK
137 B $ 133.34 0.4 % $ 334 B usaUSA
Moderna Moderna
MRNA
8.65 B $ 195.25 -2.05 % $ 76 B usaUSA
NuCana plc NuCana plc
NCNA
24.3 M $ 0.75 4.39 % $ 8.42 B britainBritain
Novartis AG Novartis AG
NVS
46.5 B $ 150.51 -0.47 % $ 292 B schweizSchweiz
Puma Biotechnology Puma Biotechnology
PBYI
130 M $ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
311 M $ 3.69 -0.67 % $ 281 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
9.25 M $ 0.79 -2.58 % $ 36.6 M usaUSA
Geron Corporation Geron Corporation
GERN
226 M $ 0.87 -4.76 % $ 580 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
149 M $ 11.54 -5.18 % $ 7.95 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
-438 M $ 4.65 -8.46 % $ 339 M usaUSA
Genmab A/S Genmab A/S
GMAB
36.7 B $ 50.36 -1.93 % $ 3.26 B danmarkDanmark
Gossamer Bio Gossamer Bio
GOSS
-123 M $ 10.69 -4.81 % $ 2.44 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
8.61 B $ 8.14 -0.73 % $ 5.53 B spainSpain
Liquidia Corporation Liquidia Corporation
LQDA
44.7 M $ 54.39 -3.96 % $ 4.68 B usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
16 B $ 47.8 -0.05 % $ 194 B britainBritain
MediciNova MediciNova
MNOV
41.6 M $ 1.3 2.36 % $ 63.8 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
-205 M $ 56.23 -3.59 % $ 4.47 B usaUSA
Pulmatrix Pulmatrix
PULM
3.59 M $ 1.24 -12.34 % $ 4.53 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
41.6 M $ 1.05 -3.67 % $ 70.7 M germanyGermany
Immunome Immunome
IMNM
634 M $ 15.69 -5.54 % $ 1.37 B usaUSA
Immuron Limited Immuron Limited
IMRN
8.07 M $ 0.9 5.87 % $ 208 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
5.17 B $ 114.5 -1.19 % $ 22.4 B usaUSA
INmune Bio INmune Bio
INMB
23.5 M $ 0.82 -8.41 % $ 20.3 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
337 B $ 14.88 0.24 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
31.3 B $ 920.38 -0.22 % $ 96.3 B usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
489 M $ 26.58 -2.37 % $ 4.25 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
1.93 B $ 1.06 -10.92 % $ 48.4 M israelIsrael
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
397 M $ 4.68 -0.53 % $ 757 M usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
7 M $ 2.73 -9.61 % $ 22.2 M usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
671 M $ 10.02 5.24 % $ 1.09 B usaUSA
Adagene Adagene
ADAG
51.9 M $ 1.8 -10.56 % $ 106 M chinaChina
Denali Therapeutics Denali Therapeutics
DNLI
1.01 B $ 18.43 1.29 % $ 3.18 B usaUSA
Pfizer Pfizer
PFE
86.8 B $ 27.4 -0.62 % $ 156 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
459 M $ 10.56 -6.26 % $ 4.38 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
27.1 M $ 11.08 -0.81 % $ 100 M usaUSA
Editas Medicine Editas Medicine
EDIT
27.3 M $ 1.63 -4.68 % $ 145 M usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
568 M $ 93.83 0.32 % $ 6.96 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
1.19 B $ 27.54 -4.24 % $ 1.6 B usaUSA